JY
SPRY icon

Jeff Yass’s ARS Pharmaceuticals SPRY Stock Holding History

Jeff Yass’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474K Buy
59,200
+8,300
+16% +$71.4K ﹤0.01% 10039
2026
Q1 		$409K Sell
50,900
-175,900
-78% -$1.69M ﹤0.01% 10157
2025
Q4 		$2.64M Sell
226,800
-33,500
-13% -$326K ﹤0.01% 5105
2025
Q3 		$2.62M Buy
260,300
+201,200
+340% +$2.89M ﹤0.01% 5233
2025
Q2 		$1.03M Buy
59,100
+1,200
+2% +$17.3K ﹤0.01% 7358
2025
Q1 		$728K Sell
57,900
-27,400
-32% -$330K ﹤0.01% 8049
2024
Q4 		$900K Sell
85,300
-162,400
-66% -$2.27M ﹤0.01% 7222
2024
Q3 		$3.59M Buy
247,700
+214,100
+637% +$2.55M ﹤0.01% 4215
2024
Q2 		$286K Buy
+33,600
New +$298K ﹤0.01% 9563
2024
Q1 		– Sell
-173,800
Closed -$952K – 13269
2023
Q4 		$952K Sell
173,800
-64,700
-27% -$283K ﹤0.01% 7105
2023
Q3 		$902K Buy
238,500
+206,000
+634% +$1.35M ﹤0.01% 6863
2023
Q2 		$218K Buy
32,500
+18,500
+132% +$123K ﹤0.01% 10117
2023
Q1 		$91.1K Buy
+14,000
New +$108K ﹤0.01% 11364
2022
Q4 		– Sell
-107,800
Closed -$569K – 13607
2022
Q3 		$569K Sell
107,800
-247,000
-70% -$1.22M ﹤0.01% 8148
2022
Q2 		$1.5M Buy
+354,800
New +$1.24M ﹤0.01% 5531
2021
Q4 		– Sell
-13,600
Closed -$136K – 13867
2021
Q3 		$136K Buy
+13,600
New +$335K ﹤0.01% 11864

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jeff Yass's SPRY Position: Q2 2026 in Review

Jeff Yass reduced its ARS Pharmaceuticals (SPRY) stake by 3.5% in Q2 2026, selling an estimated $18.3K and leaving 58,413 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #10072.

Jeff Yass first reported a position in SPRY in Q2 2022 and has held it in 14 quarters since. The position peaked at $4.48M in Q2 2025. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Jeff Yass held 58,413 shares of ARS Pharmaceuticals worth $468K as of Q2 2026.
  • Jeff Yass sold 2,124 ARS Pharmaceuticals shares in Q2 2026, an estimated $18.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10072 holding.
  • Jeff Yass first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • Jeff Yass's ARS Pharmaceuticals position peaked at $4.48M in Q2 2025.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.